{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-017115","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.117014+00:00","generated_at":"2026-05-15T05:51:31.777526+00:00","sec_items":["1.01","5.03","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate","bullets":["Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.","Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.","Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.","Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.","Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-017115","json":"https://secwatch.observer/filing/0001493152-26-017115.json","markdown":"https://secwatch.observer/filing/0001493152-26-017115.md","text":"https://secwatch.observer/filing/0001493152-26-017115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:51:31.777526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32592544f0e3793cc26da01c1adc1a3d2f30302f","claim":"Aspire Biopharma Holdings, Inc.: Filed a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, clarifying and restating provisions relating to designation and number of shares to 30,000 shares of Series A Convertible Preferred Stock (effective 2026-04-13).","evidence_excerpt":"On April 13, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Amendment”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-04-13"}],"fact_type":"governance_change"},{"claim_id":"3a420a4b48f8e2bdd6d5c28c194843690ec55290","claim":"Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors (effective 2026-02-06).","evidence_excerpt":"on February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Effective","value":"2026-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}